13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
89,870 |
27.06.24 17:35:33 |
-1,060 |
-1,17% |
0,000 |
0,000 |
90,140 |
90,930 |
|
Regeneron Pharmaceuticals |
881535 |
NASDAQ |
1.048,130 |
27.06.24 21:37:31 |
-21,030 |
-1,97% |
1.047,840 |
1.048,240 |
1.071,220 |
1.069,160 |